GlaxoSmithKline has agreed to pay the state of Idaho $2.6 million to settle claims that it overcharged Idaho Medicaid. Idaho Attorney General Lawrence Wasden believes that the manufacturer inflated the average wholesale price of its drugs; for example, the price of Wellbutrin was found to be inflated by as much as 27 percent. Of the $2.6 million settlement, $1.544 million will go into the Cooperative Welfare Fund to reimburse the federal government. The remainder will go to the state: more than $620,000 will be deposited into the state’s general fund, and $50,000 will go into the consumer protection account for the Attorney General’s investigative and legal costs.
Full content: Idaho Statesman
Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI